TWYNEO is claimed to be the first and only US Food and Drug Administration (FDA)-approved fixed-dose cream which combines tretinoin and benzoyl peroxide for treating acne vulgaris in The post S...
https://www.pharmaceutical-business-review.com/news/sol-gel-beimei-twyneo/
The latest milestone means that the company’s microbial cleanrooms are now qualified for the production of cGMP microbial biologic drugs. The validation of Scorpius’ microbial cleanrooms ...
https://www.pharmaceutical-business-review.com/news/scorpius-validation-microbial-facilities/
The collaboration will combine FogPharma’s Helicon peptide platform with ARTBIO’s AlphaDirect platform to create targeted therapies using the 212Pb isotope. The companies will jointly develop...
https://www.pharmaceutical-business-review.com/news/fogpharma-artbio-cancer-therapies/
The company initially acquired the site in 2022 and extensively renovated it. The Bronx facility is equipped with latest technology and marks a significant investment by PharmaLogic in The post...
https://www.pharmaceutical-business-review.com/news/pharmalogic-radiopharmaceutical-facility-us/
The funding attracted a diverse group of new investors, including Cormorant Asset Management, SymBiosis, Surveyor Capital, Walleye Capital, Laurion Capital Management, Tetragon Financial Group, L...
https://www.pharmaceutical-business-review.com/news/aardvark-series-c-funding-round/
This expansion, announced by New York Governor Kathy Hochul, is supported by New York State through the state’s economic development agency, Empire State Development (ESD). The state governme...
https://www.pharmaceutical-business-review.com/news/ima-life-equipment-production-site/
The collaboration is set to address the issue of relapse in patients undergoing treatment with conventional anti-CD19 CAR T-cell therapies through the use of TriCAR-T immunotherapy. As per The ...
https://www.pharmaceutical-business-review.com/news/immunoact-cell-therapy-deal/
The funding round was led jointly by ARTIS Ventures and Wing VC, with contributions from a consortium of investors including Alexandria Venture Investments, Fusion Fund, OMX Ventures, Civilizatio...
https://www.pharmaceutical-business-review.com/news/overt-bio-seed-funding/
The BLA seeks approval for the use of subcutaneous nivolumab as a monotherapy, as maintenance therapy after treatment with Opdivo plus Yervoy (ipilimumab) combination regimen, or along with The...
https://www.pharmaceutical-business-review.com/news/fda-bla-bms-nivolumab/
The financing round is co-led by 8VC and DCVC Bio, with contributions from Samsung Life Science Fund, The Children’s Hospital of Philadelphia Foundation, Benjamin Franklin Technology Partners, ...
https://www.pharmaceutical-business-review.com/news/latus-bio-54m-cns/